Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Division of Gastroenterology, Mayo Clinic, Rochester, Minnesota.
Gastroenterology. 2024 Oct;167(5):885-902. doi: 10.1053/j.gastro.2024.05.004. Epub 2024 May 14.
There has been an increased ability to investigate the human microbiota through next-generation sequencing and functional assessment. This advancement has rapidly expanded our ability to study and manipulate the gastrointestinal microbiome to mitigate disease. Fecal microbiota transplantation, a therapy that broadly transfers the entire intestinal ecosystem, has been explored as a potential therapeutic in a variety of gastrointestinal, hepatic, and extraintestinal conditions. The field, however, continues to evolve, with a movement toward precision microbiome therapeutics, individualizing care for various disorders. This review will describe the use of fecal microbiota transplantation, microbiota restoration, and precision microbiome therapeutics, focusing on gastrointestinal and hepatic diseases.
通过下一代测序和功能评估,人们对人类微生物组的研究能力得到了提高。这一进步极大地提高了我们研究和操纵胃肠道微生物组以减轻疾病的能力。粪便微生物群移植是一种广泛转移整个肠道生态系统的治疗方法,已被探索用于治疗各种胃肠道、肝脏和肠外疾病。然而,该领域仍在不断发展,朝着精准微生物组治疗方向发展,为各种疾病提供个性化护理。本综述将描述粪便微生物群移植、微生物群恢复和精准微生物组治疗的应用,重点关注胃肠道和肝脏疾病。